Maulik Nanavaty's most recent trade in Rani Therapeutics Holdings Inc - Ordinary Shares Class A was a trade of 50,000 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 50,000 | 50,000 | - | - | Director Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Dec 2024 | 101,276 | 0 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 101,276 | 101,276 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Dec 2024 | 15,423 | 0 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 15,423 | 79,317 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2023 | 101,276 | 101,276 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Dec 2023 | 101,276 | 0 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Dec 2023 | 15,423 | 63,894 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2023 | 15,423 | 15,423 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 101,276 | 101,276 | - | - | Stock Option (Right to Buy) | |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 41,416 | 41,416 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,630 | 177,822 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,630 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.17 per share. | 28 Feb 2022 | 564 | 177,258 (0%) | 0% | 44.2 | 24,912 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 11,335 | 11,335 | - | - | Performance Share Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 1,714 | 1,714 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 1,714 | 176,785 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 21 Feb 2022 | 593 | 176,192 (0%) | 0% | 42.5 | 25,232 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 2,166 | 6,500 | - | - | Restricted Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 2,166 | 174,658 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,779 | 3,558 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,779 | 175,687 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.83 per share. | 17 Feb 2022 | 750 | 173,908 (0%) | 0% | 42.8 | 32,123 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 17 Feb 2022 | 616 | 175,071 (0%) | 0% | 42.6 | 26,211 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 21,029 | 21,029 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 7,354 | 7,354 | - | - | Restricted Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,661 | 1,661 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,661 | 173,067 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.01 per share. | 15 Feb 2022 | 575 | 172,492 (0%) | 0% | 44.0 | 25,306 | Common Stock |
| Rani Therapeutics Holdings... | Maulik Nanavaty | Director | Other type of transaction at price $ 0.00 per share. | 03 Feb 2022 | 11,017 | 11,017 | - | 0 | Class A Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,175 | 173,752 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,175 | 0 | - | - | Performance Share Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.48 per share. | 01 Jan 2022 | 2,346 | 171,406 (0%) | 0% | 42.5 | 99,658 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 34,965 | 34,965 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Sale of securities on an exchange or to another person at price $ 42.59 per share. | 28 May 2021 | 78,192 | 166,869 (0%) | 0% | 42.6 | 3,330,440 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,629 | 1,630 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,629 | 245,625 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.78 per share. | 28 Feb 2021 | 564 | 245,061 (0%) | 0% | 38.8 | 21,872 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2021 | 6,303 | 6,303 | - | - | Performance Share Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,883 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,883 | 244,648 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,713 | 3,428 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,713 | 243,358 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.20 per share. | 21 Feb 2021 | 652 | 243,996 (0%) | 0% | 39.2 | 25,558 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.03 per share. | 21 Feb 2021 | 593 | 242,765 (0%) | 0% | 38.0 | 22,552 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 27,873 | 27,873 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 8,666 | 8,666 | - | - | Restricted Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 1,778 | 242,260 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 1,778 | 5,337 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.52 per share. | 17 Feb 2021 | 615 | 241,645 (0%) | 0% | 37.5 | 23,075 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 1,661 | 241,057 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 1,661 | 3,322 | - | - | Deferred Stock Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.39 per share. | 15 Feb 2021 | 575 | 240,482 (0%) | 0% | 38.4 | 22,074 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 6,477 | 241,636 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.85 per share. | 10 Feb 2021 | 2,240 | 239,396 (0%) | 0% | 38.9 | 87,024 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2021 | 9,791 | 238,784 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2021 | 9,791 | 0 | - | - | Performance Share Units | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.95 per share. | 01 Jan 2021 | 3,625 | 235,159 (0%) | 0% | 36.0 | 130,319 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Sale of securities on an exchange or to another person at price $ 40.45 per share. | 28 Aug 2020 | 38,000 | 228,993 (0%) | 0% | 40.5 | 1,537,165 | Common Stock |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2020 | 6,851 | 0 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Maulik Nanavaty | SVP & Pres, Neuromodulation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 28 Aug 2020 | 6,851 | 266,993 (0%) | 0% | 17.3 | 118,248 | Common Stock |